SCHEMBL2140246

SCHEMBL2140246

Cc1ccc(C(=O)N2CC(F)(F)OC3(CCN(C(=O)OC(C)(C)C)CC3)C2)s1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ SCD5 Q86SK9 1/20 0.39
▸ ACACB O00763 5/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.36
▸ HDAC2 Q92769 1/20 0.35
▸ GPR119 Q8TDV5 3/20 0.35
▸ SPR P35270 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35
▸ SLC6A1 P30531 1/20 0.35
▸ GPR183 P32249 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PARP1 P09874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2141007 0.85 HTR1A (0.42) HTR1AALDH1A1HPGDSLC6A1MEN1
SCHEMBL10241542 0.84 PIK3CA (0.41) HDAC1HDAC8HDAC6SCD5ACACB
SCHEMBL10241883 0.80 HPGD (0.39) HTR1AALDH1A1HPGDSLC6A1KMT2A
Trifluoroacetic Acid SCHEMBL2140604 0.77 SLC6A1 (0.35) HTR1AALDH1A1HPGDSLC6A1KMT2A
SCHEMBL2140545 0.75 CHRM2 (0.47) SCD5ACACBUSP30GPR119CYP11B2
SCHEMBL19107360 0.72 MEN1 (0.48) HDAC1ACACBHDAC2GPR119GPR183
SCHEMBL2142861 0.72 CHRM2 (0.40) HTR1AALDH1A1SLC6A1MEN1KMT2A
SCHEMBL2142232 0.72 EPHX2 (0.42) HDAC1HDAC8HDAC6SCD5HPGD
SCHEMBL19107358 0.72 POLB (0.45) SCD5ACACBALDH1A1HPGDGPR119
SCHEMBL17328248 0.72 EPHX2 (0.45) SCD5GPR119SPRPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 — — US disclosed
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 — — US disclosed
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 — — US disclosed
US-20120322788-A1 Compouds PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-12-20 — — US disclosed
US-20120322788-A1 Compouds PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-12-20 — — US disclosed
US-20120322788-A1 Compouds PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-12-20 — — US disclosed
EP-2242759-B1 COMPOUNDS ASTRAZENECA AB (SE) 2012-09-12 — — EP disclosed
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 — — US disclosed
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 — — US disclosed
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 — — US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322788-A1 Compouds PKD1, SBDS, ABCB11 HDAC1 78/4885HDAC8 358/4885HDAC6 25/4885
US-20090298807-A1 Compounds PKD1, SLC10A1, ABCB11 HDAC1 390/4885HDAC8 876/4885HDAC6 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback